Volume 13 Supplement 1

29th International Symposium on Intensive Care and Emergency Medicine

Open Access

Micafungin for the treatment of pediatric invasive fungal infections

  • A Arrieta1,
  • NL Seibel2,
  • TJ Walsh2,
  • L Arnold3 and
  • AH Groll4
Critical Care200913(Suppl 1):P313

https://doi.org/10.1186/cc7477

Published: 13 March 2009

Introduction

Pediatric patients in the ICU are highly vulnerable to invasive fungal infections [1]; Candida has been reported to be the third most common pathogen in pediatric ICU wards [2]. However, information on new antifungal therapies in children remains limited. Micafungin (MICA) is a once-daily antifungal agent of the echinocandin class.

Methods

A retrospective review of MICA pediatric data from six trials.

Results

MICA was received by 296 children for invasive candidiasis, refractory invasive candidiasis, refractory invasive aspergillosis, prophylaxis in hematopoietic stem cell transplantation (HSCT) patients, or to assess pharmacokinetics (PK). Most patients aged <1 year were premature (38/66), whereas most children aged >1 year were HSCT recipients or undergoing another therapy for a hematological malignancy (181/230). Maximum daily dose was similar for patients aged <1, 1 to 4, 5 to 8, 9 to 12 and 13 to 15 years with medians of 2.0, 1.5, 1.5, 1.9 and 1.5 mg/kg, respectively. Treatment success rates are shown in Figure 1. MICA showed linear PK, with a higher clearance in neonates than in older children and adults. Common adverse events (incidence ≥ 2%) were transient increases in transaminases, hypokalemia, hyperbilirubinemia and increased alkaline phosphatase.
Figure 1

abstract P313

Conclusion

MICA is a safe and efficacious agent for the treatment and prophylaxis of pediatric invasive fungal infections in the ICU setting.

Authors’ Affiliations

(1)
Children's Hospital
(2)
National Institute of Health
(3)
Astellas Pharma
(4)
Children's Hospital

References

  1. Filioti J, et al.: Intensive Care Med. 2007, 33: 1272-1283. 10.1007/s00134-007-0672-5PubMedView ArticleGoogle Scholar
  2. Raymond J, et al.: Infect Control Hosp Epidemiol. 2000, 21: 260-263. 10.1086/501755PubMedView ArticleGoogle Scholar

Copyright

© Arrieta et al; licensee BioMed Central Ltd. 2009

This article is published under license to BioMed Central Ltd.

Advertisement